Vancouver-based RNA medicines company Borealis Biosciences has emerged from stealth with $150 million in financing from investors Versant Ventures and Novartis to combat kidney disease remain. The company builds upon the success Chinook Therapeutics, which Versant founded in 2019 before Novartis acquired it last year.
Borealis’ 25-person team has worked at the forefront of kidney research and RNA therapeutics for more than a decade, cultivating “an ideal environment for an exceptional founding team to continue to pioneer renal science and drug discovery,” according to Fiona Marshall, president of biomedical research at Novartis. Borealis’ research site is based in Vancouver at the 23,000-square-foot operating site formerly leased by Chinook.
Want to know more? Check out the source code on Techcouver.